Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer

Part of the Medical Radiology book series (MEDRAD)


The use of chemotherapy in addition to radiation has unquestionably improved outcomes in both small cell and non-small cell lung cancer. However, as in advanced disease, a plateau in efficacy has been reached. Over the past several decades numerous receptors and pathways responsible for normal cellular growth, maintenance and development have been identified. Derangements of these pathways frequently result in cancer, perpetuate cancer or result in resistance to treatment with chemotherapy and/or radiation. New agents targeting these pathways are now becoming available. Many of these have the potential to potentiate existing agents and/or radiation. In addition, radiation can itself be targeted by coupling radioisotopes to a moiety that will bind with receptors that are aberrantly expressed in cancer.


Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Small Cell Lung Cancer Interstitial Lung Disease Epidermal Growth Factor Receptor Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Albert JM, Kim KW, Cao C, Lu B (2006) Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5(5):1183–1189PubMedCrossRefGoogle Scholar
  2. Albert JM, Cao C, Kim KW et al (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13(10):3033–3042PubMedCrossRefGoogle Scholar
  3. Altorki NK, Keresztes RS, Port JL et al (2003) Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21(14):2645–2650PubMedCrossRefGoogle Scholar
  4. Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51–62PubMedCrossRefGoogle Scholar
  5. Andrews PD, Knatko E, Moore WJ, Swedlow JR (2003) Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 15:672–683PubMedCrossRefGoogle Scholar
  6. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Nat Cancer Inst 85:1327–1333PubMedCrossRefGoogle Scholar
  7. Blumenschein GR Jr, Paulus R, Curran WJ et al (2011) Phase II study of cetuximab in combination with chemoradiation in patients with stage III A/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29(17):2312–2318PubMedCrossRefGoogle Scholar
  8. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEJM 354(6):567–578PubMedCrossRefGoogle Scholar
  9. Calabrese CR, Almassy R, Barton S et al (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96(1):56–67PubMedCrossRefGoogle Scholar
  10. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66(20):10040–10047PubMedCrossRefGoogle Scholar
  11. Cappuzzo F, Ciuleanu T, Stelmakh L (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529PubMedCrossRefGoogle Scholar
  12. Carey LA, Sharpless NE (2011) PARP and cancer—if it’s broke, don’t fix it. N Engl J Med 364:277–279PubMedCrossRefGoogle Scholar
  13. Chen YJ, Lin CP, Hsu ML, Shieh HR, Chao NK, Chao KS (2011) Sonic hedgehog signaling protects human hepatocellular carcinoma cells against ionizing radiation in an autocrine manner. Int J Radiat Oncol Biol Phys 80(3):851–859 [Epub ahead of print]PubMedCrossRefGoogle Scholar
  14. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8):3328–3335PubMedGoogle Scholar
  15. Choong NW, Mauer AM, Haraf DJ et al (2008) Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 3(9):1003–1011PubMedCrossRefGoogle Scholar
  16. Chopra A (2008) 188Re-labeled humanized monoclonal anti-epidermal growth factor receptor antibody.Molecular imaging and contrast agent database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US), 2004–2010. 2008 August 04 [updated 2008 September 02]Google Scholar
  17. Cosaceanu D, Iliescu G, Castro J et al (2004) In vitro enhancement of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Proc Amer Assoc Cancer Res 45:1 Abstract #1299Google Scholar
  18. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II southwest oncology group study (S0339). J Thorac Oncol 4:87–92PubMedCrossRefGoogle Scholar
  19. De Ruysscher D, Bussink J, Rodrigus P, Kessels A, Dirx M, Houben R, Wanders R (2007) Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial. Radiother Oncol 84(1):23–25PubMedCrossRefGoogle Scholar
  20. Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15(5–6):243–249 Epub 2010 January 29PubMedCrossRefGoogle Scholar
  21. Dungey FA, Löser DA, Chalmers AJ (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72(4):1188–1197PubMedCrossRefGoogle Scholar
  22. Edelman MJ (2005) The potential role of bortezomib in chemoradiotherapy of non-small cell lung cancer. Clin Lung Cancer 7(2):S64–S66PubMedCrossRefGoogle Scholar
  23. Edelman MJ (2011) Apricoxib: a novel COX-2 inhibitor for oncology. Drugs of the future (in press)Google Scholar
  24. Edelman MJ, Watson D, Xiaofei W et al (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy–cancer and Leukemia Group B trial 30203. J Clin Oncol 26:848–855PubMedCrossRefGoogle Scholar
  25. Edelman MJ, Clamon G, Kahn D, Magram M, Line BR (2009) Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 somatostatin analogue P2045. J Thor Oncol 4(12):1550–1554CrossRefGoogle Scholar
  26. Edelman MJ, Burrows W, Krasna MJ, Suntharalingam M (2010) Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage III non-small cell lung cancer. Lung Cancer 68(1):84–88PubMedCrossRefGoogle Scholar
  27. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552PubMedCrossRefGoogle Scholar
  28. Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF (2010) Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 77:253–260PubMedCrossRefGoogle Scholar
  29. Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22:777–784PubMedCrossRefGoogle Scholar
  30. Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H (2009) Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer 66:64–74PubMedCrossRefGoogle Scholar
  31. Govindan R, Bogart J, Wang X et al (2009) Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer. Proc Am Soc Clin Oncol 27:383s (abstract 7505)Google Scholar
  32. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, Maione P (2010) The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs 19(5):631–639PubMedCrossRefGoogle Scholar
  33. Groen H, Hochstenbag MM, van Putten JW et al (2009) A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): the NVALT-4 study. J Clin Oncol 27:15 (suppl; abstr 8005)CrossRefGoogle Scholar
  34. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q (2007) Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 67(21):10436–10444PubMedCrossRefGoogle Scholar
  35. Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22:785–794PubMedCrossRefGoogle Scholar
  36. Herbst RS, Prager D, Fehrenbacher L et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899PubMedCrossRefGoogle Scholar
  37. Hu SY, Duan HF, Li QF, Yang YF, Chen JL, Wang LS, Wang H (2009) Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage. Acta Pharmacol Sin 30(10):1415–1420PubMedCrossRefGoogle Scholar
  38. Jassem J, Langer CJ, Karp DD et al (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer. J Clin Oncol 28(15S):539a (abstract 7500)Google Scholar
  39. Johnson DH, Fehrenbacher L, Novotny WF (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191PubMedCrossRefGoogle Scholar
  40. Karp DD, Pollak MN, Cohen RB, Eisenberg PD et al (2009a) Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin. J Thorac Oncol 4:1397–1403PubMedCrossRefGoogle Scholar
  41. Karp DD, Paz-Ares LG, Novello S et al (2009b) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516–2522PubMedCrossRefGoogle Scholar
  42. Kelly K, Chansky K, Gaspar LE et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450–2456 Epub 2008 March 31PubMedCrossRefGoogle Scholar
  43. Khambata-Ford S, Harbison CT, Hart LL et al (2010) Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28(6):918–927PubMedCrossRefGoogle Scholar
  44. Khan K, Araki K, Wang D et al (2010) Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 32(3):381–391PubMedGoogle Scholar
  45. Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3(2):166–179 Epub 2010 December 26PubMedGoogle Scholar
  46. Kubo M, Nakamura M, Tasaki A et al (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64:6071–6074PubMedCrossRefGoogle Scholar
  47. Kuhn DJ, Orlowski RZ, Bjorklund CC (2011) Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11(3):285–295PubMedCrossRefGoogle Scholar
  48. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703 Erratum in: N Engl J Med 2011 February 10;364(6):588PubMedCrossRefGoogle Scholar
  49. Lee JM, Mao JT, Krysan K, Dubinett SM (2007) Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 3(2):149–153PubMedCrossRefGoogle Scholar
  50. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD (2005) A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non–small cell lung cancer. Clin Cancer Res 11(9):3342–3348PubMedCrossRefGoogle Scholar
  51. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG (2008) A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 88(2):258–268PubMedCrossRefGoogle Scholar
  52. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  53. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4:1002–1009PubMedCrossRefGoogle Scholar
  54. Lynch TJ, Patel T, Dreisbach L (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28(6):911–917 Epub 2010 January 25PubMedCrossRefGoogle Scholar
  55. Maemondo M, Inoue A, Kobayashi K (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388PubMedCrossRefGoogle Scholar
  56. Mendelsohn J, Kawamoto T, Sato G, Sato J (1990) Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. United States Patent #4,943,533. July 24Google Scholar
  57. Milenic DE, Brechbiel MW (2004) Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 3(4):361–370PubMedGoogle Scholar
  58. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957 Epub 2009 August 19PubMedCrossRefGoogle Scholar
  59. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H (2009) A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage III A/B non-small cell lung cancer. Clin Cancer Res 15(6):2158–2165PubMedCrossRefGoogle Scholar
  60. O’Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP (2001) Somatostatin, its receptors and analogs, in lung cancer. Chemother 47(Suppl 2):78–108Google Scholar
  61. O’Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214PubMedCrossRefGoogle Scholar
  62. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci 304:1497–1500CrossRefGoogle Scholar
  63. Pirker R, Pereira JR, Szczesna A (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531PubMedCrossRefGoogle Scholar
  64. Pirker R, Paz Ares L, Eberhardt W et al (2011) Epidermal growth factor receptor expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer. J Thor Oncol 6(Suppl 2):S276Google Scholar
  65. Plummer R, Jones C, Middleton M (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14(23):7917–7923PubMedCrossRefGoogle Scholar
  66. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA (2010) Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 5(10):1623–1629PubMedCrossRefGoogle Scholar
  67. Ramalingam SS, Dahlberg SE, Langer CJ (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group rial 4599. J Clin Oncol 26(1):60–65PubMedCrossRefGoogle Scholar
  68. Ramalingam SS, Maitland ML, Frankel P et al (2010a) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56–62PubMedCrossRefGoogle Scholar
  69. Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR (2010b) Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 116(16):3903–3909PubMedCrossRefGoogle Scholar
  70. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227–1234 Epub 2009 Feb 2. Erratum in: J Clin Oncol 2009;27:2415PubMedCrossRefGoogle Scholar
  71. Rudin CM, Hann CL, Laterra J et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173–1178PubMedCrossRefGoogle Scholar
  72. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550 Erratum in: N Engl J Med 2007;356:318PubMedCrossRefGoogle Scholar
  73. Scagliotti G, Novello S, von Pawel J (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28(11):1835–1842 Epub 2010 March 8PubMedCrossRefGoogle Scholar
  74. Schiller JH, Larson T, Ou SH et al (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27(23):3836–3841 Epub 2009 July 13PubMedCrossRefGoogle Scholar
  75. Schmitt A, Bernhardt P, Nilsson O et al (2004) Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med 45:1542–1548PubMedGoogle Scholar
  76. Shaked Y, Henke E, Roodhart JM et al (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14(3):263–273PubMedCrossRefGoogle Scholar
  77. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRefGoogle Scholar
  78. Smith SL, Bowers NL, Betticher DC et al (2005) Overexpression of aurora-B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele and correlates with the level of genetic instability. Br J Cancer 93:719–729PubMedCrossRefGoogle Scholar
  79. Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26(4):650–656PubMedCrossRefGoogle Scholar
  80. Soria JC, Shepherd FA, Douillard JY et al (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20:1674–1681PubMedCrossRefGoogle Scholar
  81. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA (2010) Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28(1):43–48 Epub 2009 November 9PubMedCrossRefGoogle Scholar
  82. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E (2009) The aurora-B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 8(19):3172–3181 Epub 2009 October 4PubMedCrossRefGoogle Scholar
  83. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A (2010) Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16(23):5900–5907PubMedCrossRefGoogle Scholar
  84. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731PubMedCrossRefGoogle Scholar
  85. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS, Larsen LA (2006) Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52:281–290PubMedCrossRefGoogle Scholar
  86. Von Hoff DD, Lorusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164–1172CrossRefGoogle Scholar
  87. Wang J, Xia TY, Wang YJ et al (2011) Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys [Epub ahead of print]Google Scholar
  88. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 22:69CrossRefGoogle Scholar
  89. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250PubMedCrossRefGoogle Scholar
  90. Yang L, Xie G, Fan Q, Xie J (2010) Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29(4):469–481 Epub 2009 November 23PubMedCrossRefGoogle Scholar
  91. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group. N Engl J Med 364(6):514–523PubMedCrossRefGoogle Scholar
  92. Zhou Q, Bai M, Su Y (2004) Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells. Chin Med J 117:1642–1649PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  1. 1.University of Maryland Greenebaum Cancer CenterBaltimoreUSA

Personalised recommendations